Aigner Achim
Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, University of Leipzig. Germany.
Biochem Biophys Res Commun. 2025 Sep 25;781:152512. doi: 10.1016/j.bbrc.2025.152512. Epub 2025 Aug 16.
RNA molecules offer attractive therapeutic strategies in oncology, based on mechanisms of action different to existing medications. The therapeutic application of RNAs, however, is still associated with major bottlenecks, including poor stability and pharmacokinetics. Non-viral nanoparticle formulations represent systems for RNA protection, delivery and cell internalization. They have to meet defined requirements for providing sufficient efficacy, specificity and biocompatibility. Moreover, the selection of the RNA drug as payload is of major relevance. As a result of intense research over the past decades, a wide variety of different RNA classes are available for interference with pathophysiological processes. This review provides an overview of various RNA classes as drug candidates, including RNAs mediating loss-of-function (siRNAs for gene knockdown, sgRNAs for gene knockout, gene- or base-editing), gain-of-function (mRNA, sa-mRNA, circRNA for ectopic overexpression) or modulation of gene expression (miRNAs, antimiRs or circRNAs for miRNA inhibition), among others. Dependent on the target organ, target cell and type of RNA molecule, different nanoparticle systems can provide efficient RNA formulations. New therapeutic strategies may also cover combinations of different types of RNAs, associated with different properties and thus requiring even more sophisticated nanocarriers for their delivery. The various classes of nanocarriers available for RNA formulation are reviewed and discussed as well. Beyond therapeutic in vivo application, RNA-based strategies may also be of relevance in cell-based therapies, for non-viral ex vivo modification of immune cells. While this would offer advantages over existing viral transduction strategies, it will also rely on sufficiently efficient non-viral systems for cell modification. Overall, nonviral systems for the delivery of RNA therapeutics are needed to fulfil the potential of these approaches in the clinic.
基于与现有药物不同的作用机制,RNA分子为肿瘤学提供了有吸引力的治疗策略。然而,RNA的治疗应用仍然存在主要瓶颈,包括稳定性差和药代动力学问题。非病毒纳米颗粒制剂代表了用于RNA保护、递送和细胞内化的系统。它们必须满足提供足够疗效、特异性和生物相容性的特定要求。此外,选择RNA药物作为有效载荷至关重要。经过过去几十年的深入研究,有多种不同类型的RNA可用于干扰病理生理过程。本综述概述了各种作为候选药物的RNA类型,包括介导功能丧失的RNA(用于基因敲低的小干扰RNA、用于基因敲除的引导RNA、基因或碱基编辑)、功能获得的RNA(用于异位过表达的信使RNA、自扩增信使RNA、环状RNA)或基因表达调节的RNA(用于抑制微小RNA的微小RNA、抗微小RNA或环状RNA)等。根据靶器官、靶细胞和RNA分子类型的不同,不同的纳米颗粒系统可以提供有效的RNA制剂。新的治疗策略还可能涵盖不同类型RNA的组合,这些RNA具有不同的特性,因此需要更复杂的纳米载体来递送它们。本文还综述和讨论了可用于RNA制剂的各类纳米载体。除了体内治疗应用外,基于RNA的策略在细胞治疗中也可能具有相关性,用于免疫细胞的非病毒体外修饰。虽然这将比现有的病毒转导策略具有优势,但它也将依赖于足够高效的非病毒系统进行细胞修饰。总体而言,需要非病毒系统来递送RNA治疗剂,以实现这些方法在临床上的潜力。